Clinical trials: malaria
Malaria
Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet
The primary objective of this study is to determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose…
- Trial name
- NCT00682630
- Testing
- pyronaridine artesunate clinical trial reference tablets, pyronaridine artesunate to-be-marketed tablets
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Plasmodium Falciparum Malaria
Targeted Chemo-elimination (TCE) of Malaria
The overall aim of this study is two fold: 1. to pilot targeted chemo-elimination of plasmodium falciparum malaria in known areas of artemisinin resistance in South East Asia. 2.
- Trial name
- TME (NCT01872702)
- Testing
- malaria elimination using DP and low-dose primaquine
- Where
- 5 sites in Burma, Cambodia and 3 more
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP
This is an open label phase I study, to assess the safety of a novel malaria vaccine, AdCh63 ME-TRAP, simian adenovirus encoding Plasmodium falciparum antigens.
- Trial name
- NCT00890019
- Testing
- AdCh63 ME-TRAP, AdCh63 ME-TRAP; MVA ME-TRAP
- Where
- 2 sites in United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria
Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
Malaria is one of the major infectious diseases in the world with a tremendous impact on the quality of life significantly contributing to the ongoing poverty in endemic countries.
- Trial name
- EHMI9 (NCT01236612)
- Testing
- Chloroquine prophylaxis, Immunization, Plasmodium falciparum Bloodstage challenge
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria (Plasmodium Falciparum)
Malaria CVD 36000; Gates INV090205
In order to control infections, the investigators must first detect them. Biosensor devices may allow early detection and intervention for infectious diseases, helping the investigators to recognize infections early, and allow…
- Trial name
- NCT07558122
- Testing
- PfSPZ Challenge (NF54), Wearable Biosensor Devices
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites
It is possible to safely protect human volunteers immunized with P. vivax irradiated sporozoites from P. vivax challenge with live sporozoites.
- Trial name
- SPZ-Irrad (NCT01082341)
- Testing
- Immunization with P. vivax irradiated sporozoites
- Where
- Colombia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults
Background: Malaria is caused by small germs carried by mosquitoes. People can get malaria if an infected mosquito bites them. Malaria destroys red blood cells and reduces oxygen in the blood.
- Trial name
- NCT01988636
- Testing
- PfSPZ Vaccine
- Where
- Mali
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Subjects
Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects
This was a single-center study using induced blood stage malaria infection to characterize the activity of ACT-451840 against early Plasmodium falciparum blood stage infection
- Trial name
- NCT02223871
- Testing
- ACT-451840:, Plasmodium falciparum-infected human erythrocytes:, Artemether 20 mg and lumefantrine 120mg combination tablet:
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Malaria
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.
- Trial name
- NCT00866619
- Testing
- Malaria Vaccine 257049, Meningococcal C Conjugate Vaccine, Cell-culture rabies vaccine
- Where
- 10 sites in Burkina Faso, Gabon and 5 more
- Volunteers
- 15,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant
The purpose of this study is to determine the safety of and immune response to a preventive malaria vaccine, MSP1 42-C1/Alhydrogel, in healthy adults.
- Trial name
- NCT00320658
- Testing
- MSP1 42-C1/Alhydrogel, CPG 7909
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Pregnancy
Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi
This study aims to compare the efficacy of monthly IPTp-DP with monthly IPTp-SP to determine if IPTp-DP is associated with a reduction in malaria infection at delivery among HIV-negative women in an area with high levels of SP…
- Trial name
- STOPMIP-MW (NCT03009526)
- Testing
- Sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine
- Where
- Malawi
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Kamuzu University of Health Sciences
Malaria
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics…
- Trial name
- CHMI-trans1 (NCT02836002)
- Testing
- Sulfadoxine-pyrimethamine (low dose), Piperaquine (low dose), Sulfadoxine-pyrimethamine (high dose)
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Falciparum Malaria
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
This is a phase Ib double-blind randomized placebo controlled age-deescalating trial to assess sagety and immunogenicity of two virosome formulated anti-malaria vaccine components (PEV 301 and PEV 302) administered in combination…
- Trial name
- PMAL03 (NCT00513669)
- Testing
- PEV 301& 302 in virosomes, Inflexal V (active comparator)
- Where
- Tanzania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Plasmodium Falciparum Malaria
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
The objective of this study was to evaluate the safety of a candidate malaria vaccine (PfAMA-1) at 3 doses given at monthly intervals of 2 different dosages of AMA-1 (10 μg or 50 μg ) adjuvanted either with alum hydroxide or…
- Trial name
- NCT00730782
- Testing
- PfAMA-1-FVO[25-545]
- Where
- 2 sites in Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Prevention of Malaria Transmission and Clinical Malaria
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
This is a Phase 1, individually randomized, double-blind, dose escalating study designed to evaluate the safety, tolerability, and immunogenicity of Pfs230D1 conjugate vaccines, R21 nanoparticle vaccine, or their combination…
- Trial name
- NCT06507605
- Testing
- R21, Pfs230D1-CRM197, Pfs230D1-EPA
- Where
- Mali
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria
Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib
P27A study is designed as a randomized phase Ia/Ib trial to evaluate the safety and immunogenicity of the blood stage candidate vaccine P27A against P.
- Trial name
- P27A (NCT01949909)
- Testing
- CH-Alum50, CH-GLA2.5/50, TZ Ver
- Where
- 2 sites in Switzerland, Tanzania
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Plasmodium Falciparum Malaria
EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
Malaria, a disease responsible for over one million deaths per year, is caused by a germ spread by mosquito bites. The purpose of this study is to evaluate a vaccine designed for the prevention of malaria caused by the parasite…
- Trial name
- NCT01169077
- Testing
- EP-1300
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria, Falciparum
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P.
- Trial name
- NCT02329301
- Testing
- MDA with DHAp (Eurartesim), Focal MDA with DHAp (Eurartesim)
- Where
- Zambia
- Volunteers
- 2,430 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Falciparum
Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S
The purpose of this study is to see if two new malaria vaccines called FMP1 and RTSS, combined with an adjuvant (called SBAS2) which helps stimulate the body's immune system, are safe, demonstrate an immune response through blood…
- Trial name
- MAL019 (NCT01556945)
- Testing
- FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine
Background: Malaria is a disease that is spread by mosquitoes. Researchers are looking for a vaccine that can prevent mosquitoes from transmitting malaria to people.
- Trial name
- NCT01867463
- Testing
- Pfs25-EPA/Alhydrogel, Euvax B, Menactra
- Where
- Mali
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)